Skip to main content

Table 1 Clinical and epidemiological characteristics of HIV/HCV-coinfected patients

From: Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study

Characteristics All patients
No. (%) 220 (100%)
Male, n (%) 162 (73.6%)
Age, years 39.8 (37.4; 44)
HIV acquired by IDU, n (%) 193 (87.7%)
Years since HCV infection 21.3 (17.1; 24.4)
Prior AIDS, n (%) 60 (27.3%)
cART, n (%) 183 (83.2%)
Time on cART, years 4.4 (2.5; 6.7)
Current cART protocols, n (%)
 PI-based 50 (22.7%)
 NNRTI-based 114 (51.8%)
 NRTI-based 129 (58.6%)
Metabolic markers
 BMI, kg/m2 22.4 (20.8; 24.6)
 BMI ≥25 kg/m2 50 (22.9%)
 HOMA 2.10 (1.27; 3.73)
 HOMA ≥3 71 (33.5%)
HIV markers
 Nadir CD4+, T cells/μL 192 (84; 318)
 CD4+, T cells/μL 467 (324; 672)
 HIV-RNA <50 copies/mL, n (%) 162 (73.6%)
HCV markers, n (%)
 HCV-RNA ≥500.000 IU/ml 162 (74.7%)
 HCV genotype 216 (98.2%)
 HCV-GT1 123 (55.9%)
 HCV-GT2 5 (2.3%)
 HCV-GT3 50 (22.7%)
 HCV-GT4 38 (17.3%)
Metavir score, n (%)
 Significant fibrosis (F ≥ 2) 109 (49.5%)
 Advanced fibrosis (F ≥ 3) 49 (23.3%)
 Cirrhosis (F4) 23 (10.5%)
 Moderate activity grade (A ≥ 2) 114 (52.8%)
 Severe activity grade (A3) 24 (11.1%)
Fibrosis indexes
 APRI 0.75 (0.45; 1.30)
 APRI ≥1.5 36 (17.2%)
 FIB-4 1.43 (1.03; 2.03)
 FIB-4 ≥3.25 20 (9.6%)
  1. Values expressed as absolute numbers (%) and median (percentile 25; percentile 75).
  2. AIDS acquired immunodeficiency syndrome, APRI aspartate aminotransferase to platelet ratio, BMI body mass index, cART combination antiretroviral therapy, HCV hepatitis C virus, HCV-RNA HCV plasma viral load, HIV human immunodeficiency, HIV-RNA HIV plasma viral load, HOMA homeostasis model assessment, IDU intravenous drug users, NNRTI no nucleoside analog reverse-transcriptase inhibitors, NRTI nucleoside analog reverse-transcriptase inhibitors, PI protease inhibitors.